Lilly has 11 obesity drugs in its pipeline and wants to develop more ... Eli Lilly will invest $4.5 billion to ... Any new advances could help Lilly become the first trillion ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

INDIANAPOLIS, Feb. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2022. "2023 is an inflection point for Lilly - a chance ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

Eli Lilly (LLY) has outperformed the S&P index and its competitors during the past 5 years, LLY has a broad product portfolio, a robust pipeline that is built to power market performance.

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Cost control and the advancement of its solid Phase III pipeline will be critical to long-term success. Eli Lilly has 7 molecules in Phase III development, 22 molecules in Phase II development and ...